Articles by Damian McEntegart - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Damian McEntegart

Damian McEntegart

manager

Damian McEntegart, MSc, is statistics and medication forecasting manager for ClinPhone Group Ltd., Lady Bay House, Meadow Grove, Nottingham, UK, +44 115 955 7333, fax +44 115 955 7555, email:dmcenteg@clinphone.com.

Articles
The Adaptive Advantage
June 1, 2008

With help from technology, adaptive trials can enhance dose selection and reduce time between phases.

Blinded by Science with Adaptive Designs
March 1, 2007

Interactive voice response systems are a good match for adaptive clinical trials and can help keep investigators in the dark.

Blinded by Science with Adaptive Designs
March 1, 2007

Interactive voice response systems are a good match for adaptive clinical trials and can help keep investigators in the dark.

Optimizing the Supply Chain Through Trial Simulation
July 1, 2004

Monte Carlo simulations account for recruitment variability by using a random number generator to determine the site’s recruitment for each month, similar to rolling a die.

Forced Randomization: When Using Interactive Voice Response Systems
October 1, 2003

Interactive voice response systems are commonly used in clinical trials to manage the flow of trial medication supplies to sites and to manage the allocation of these supplies to individual subjects. Other advantages and uses include access to real-time information for trial managers, collection of diary card data directly from subjects, and as an aid to subject recruitment.1

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
FindPharma Custom Search
Click here